Angel Y, Spitzer A, Henig O, et al. - In this single-center, retrospective cohort study, researchers sought to estimate the correlation of vaccination with the Pfizer-BioNTech BNT162b2 vaccine with symptomatic and asymptomatic SARS-CoV-2 infections among healthcare workers. This investigation was carried out at a tertiary medical center in Tel Aviv, Israel. In total, 6,710 healthcare workers (mean [SD] age, 44.3 [12.5] years; 4465 [66.5%] women) were followed up for a median period of 63 days; 5,953 healthcare workers (88.7%) received at least 1 dose of the BNT162b2 vaccine, 5,517 (82.2%) received 2 doses, and 757 (11.3%) were not vaccinated. Receiving the BNT162b2 vaccine vs no vaccine was associated with a significantly lower incidence of symptomatic and asymptomatic SARS-CoV-2 infection more than 7 days after the second dose among health care workers at a single center in Tel Aviv, Israel. The observational design limits the findings.